<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Therapeutics on FinanClub</title>
    <link>https://finan.club/tags/therapeutics/</link>
    <description>Recent content in Therapeutics on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 12 Dec 2023 13:49:15 +0000</lastBuildDate><atom:link href="https://finan.club/tags/therapeutics/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CERE</title>
      <link>https://finan.club/us/cere/</link>
      <pubDate>Tue, 12 Dec 2023 13:49:15 +0000</pubDate>
      
      <guid>https://finan.club/us/cere/</guid>
      <description>score:197
Chances: AbbVie&amp;rsquo;s acquisition of Cerevel Therapeutics for $8.7 billion indicates a significant growth opportunity in the neuroscience sector Cerevel Therapeutics has a robust pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases like schizophrenia, Parkinson&amp;rsquo;s disease, and mood disorders Risks: The success of Cerevel Therapeutics&amp;rsquo; product candidates such as CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936 is not guaranteed Score:197 chances characters count - risks characters count = -803</description>
    </item>
    
  </channel>
</rss>
